Market expectations of a decline in Henan Taloph Pharmaceutical's revenue performance and slower growth compared to the industry average may contribute to its low P/S ratio. Shareholders' wariness of the company's ability to keep up with industry growth could be a factor in the declining share price.
Henan Taloph's lower P/S ratio may be justified due to slower growth rates than industry rivals. Doubts about the company's ability to maintain robust growth in line with industry may hinder share price recovery.
太龙药业股票讨论区
暂无评论